EconomyArriVent plunge highlights risks of China’s biotech expansion overseas

Shares of US-listed ArriVent BioPharma fell nearly 47 per cent after firmonertinib, a cancer drug licensed from China, failed to meet its main goal in a phase 3 trial. Analysts said the setback underscored the difficulties Chinese biotech companies face as they expand into global markets. The drug was originally developed by Shanghai Allist Pharmaceuticals.

ArriVent BioPharmaChinese biotechclinical trialcancer drug

SSouth China Morning Post★★☆☆☆2026-10-07 04:20Original